Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyphenon E in Cirrhosis
NCT03278925Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of green tea extract in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Change in gamma-hydroxy-1,N(2)-propanodeoxyguanosine expression at 24 weeks. Started Aug 2018; status: active, not recruiting.
02
Drugs
green tea extract
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03278925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278925.